PEDIATRIC ONCOLOGY GROUP

位于圣路易斯的华盛顿大学医学中心是39所 正式成员机构、48个附属机构、12个联合体和9个CCOP 儿科肿瘤学小组的机构， 资源和科学知识来研究自然历史， 儿童癌症，制定和比较有效的治疗方案， 研究新的抗癌药物的毒性和有效性， 儿童癌症的治疗此外，肿瘤标本和 偶尔收集正常组织和血液样本以确定 更多关于癌症的基本生物学和病理学。组 流行病学、癌症控制、药理学和 药代动力学华盛顿大学医学院的研究人员 中心包括儿科肿瘤学家，放射科医生，放射科医生， 肿瘤学家、细胞遗传学家、神经学家、外科医生和病理学家。所有 患有恶性疾病的儿童被置于合作小组协议中， 如果他们有资格并且获得了知情同意。数据 在患者接受研究方案时入组， 研究结束时，以及停止治疗时，提交给统计组 数据分析、解释和最终出版办公室。的 华盛顿大学医学中心的研究人员在多个 本集团的行政及研究能力。诊断 研究、病理结果、手术程序和治疗计划 对于所有新的病人和复发的病人， 肿瘤委员会会议。首席研究员有第一阶段合同 并与其他16个POG机构合作， 新药剂的耐受剂量沿着药理学，如果 这是指药剂的生物反应。

The Washington University Medical Center in St. Louis is one of the 39 full member institutions, 48 affiliate, 12 consortia and 9 CCOP institutions of the Pediatric Oncology Group who has pooled their patient resources and scientific expertise to study the natural history of childhood cancer, develop and compare effective therapeutic regimens and investigate the toxicity and effectiveness of new anticancer agents in the treatment of children with cancer. Additionally tumor specimens and occasionally normal tissue and blood samples are collected to determine more about the basic cancer biology and pathology of the disease. Group studies are ongoing in epidemiology, cancer control, pharmacology and pharmacokinetics. The investigators at the Washington University Medical Center include pediatric oncologists, radiologists, radiation oncologists, cytogenetists, neurologists, surgeons, and pathologists. All children with malignant disease are placed on cooperative group protocols if they are eligible and if informed consent is obtained. Data accessioned at the time the patient is placed on study protocol, during the study, and when off therapy is submitted to the Group Statistical Office for data analysis, interpretation and eventual publication. The investigators at Washington University Medical Center serve in multiple administrative and research capacities for the Group. The diagnostic studies, pathological findings, surgical procedure and therapeutic plan for all new patients and patients who relapse are discussed at the weekly Tumor Board Conference. The Principal Investigator has a phase I contract and works with 16 other POG institutions to establish the maximum tolerated dose of a new agent along with the pharmacology and, if indicated, the biologic response of the agent.